Grade ≥ 3 adverse events were observed in 42.3% of patients (Supplementary Material S6); the most common were neutropenia (19%), diarrhoea (12%), skin and subcutaneous disorders, elevated alanine transaminase (5% each), and paronychia (3%). The gene discussed is GPT; the disease is neutropenia.